Synthetic Biologics Stock Forecast, Price & News

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Is Synthetic Biologics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synthetic Biologics stock.
View analyst ratings for Synthetic Biologics or view top-rated stocks.

What stocks does MarketBeat like better than Synthetic Biologics?

Wall Street analysts have given Synthetic Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synthetic Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 23,800 shares, an increase of 28.0% from the August 15th total of 18,600 shares. Based on an average trading volume of 2,060,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's shares are sold short.
View Synthetic Biologics' Short Interest.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Synthetic Biologics.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01.
View Synthetic Biologics' earnings history.

How has Synthetic Biologics' stock price been impacted by Coronavirus?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYN shares have increased by 37.4% and is now trading at $0.4945.
View which stocks have been most impacted by COVID-19.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics shares reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

1 brokerages have issued 12-month price objectives for Synthetic Biologics' stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Synthetic Biologics' share price to reach $2.50 in the next year. This suggests a possible upside of 405.6% from the stock's current price.
View analysts' price targets for Synthetic Biologics or view top-rated stocks among Wall Street analysts.

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:

• Steven A. Shallcross, CEO, CFO, Secretary, Treasurer & Director
• Michael Kaleko, Senior Vice President-Research & Development
• Vincent I. Perrone, Director-Communication

Who are some of Synthetic Biologics' key competitors?

Some companies that are related to Synthetic Biologics include Sernova (SEOVF), Vincerx Pharma (VINC), Frequency Therapeutics (FREQ), Paratek Pharmaceuticals (PRTK), Harrow Health (HROW), iBio (IBIO), Impel NeuroPharma (IMPL), Alpine Immune Sciences (ALPN), Mustang Bio (MBIO), Atreca (BCEL), Oncorus (ONCR), Immunic (IMUX), Adicet Bio (ACET), Galectin Therapeutics (GALT) and Kamada (KMDA).
View all of SYN's competitors.

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), CorMedix (CRMD), Idera Pharmaceuticals (IDRA), Ampio Pharmaceuticals (AMPE) and Navidea Biopharmaceuticals (NAVB).

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.72%), State Street Corp (0.36%), Virtu Financial LLC (0.19%), Blair William & Co. IL (0.13%), MSD Partners L.P. (0.09%) and Bridgeway Capital Management LLC (0.06%).
View institutional ownership trends for Synthetic Biologics.

Which major investors are selling Synthetic Biologics stock?

SYN stock was sold by a variety of institutional investors in the last quarter, including MSD Partners L.P., Virtu Financial LLC, and Bridgeway Capital Management LLC.
View insider buying and selling activity for Synthetic Biologics or view top insider-selling stocks.

Which major investors are buying Synthetic Biologics stock?

SYN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Blair William & Co. IL, and Geode Capital Management LLC.
View insider buying and selling activity for Synthetic Biologics or or view top insider-buying stocks.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.49.

How much money does Synthetic Biologics make?

Synthetic Biologics has a market capitalization of $65.30 million.

How many employees does Synthetic Biologics have?

Synthetic Biologics employs 10 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

Where are Synthetic Biologics' headquarters?

Synthetic Biologics is headquartered at 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at (301) 417-4364 or via email at [email protected].